KDM3A and cancer: Because JMJD1A is overexpressed in many kinds of tumours28 and promotes cancer cell progression and invasion by epigenetically activating transcription of β-catenin and its target genes29, the readily available IOX1 provides a potent antibody-free chemo-immunotherapy paradigm for cancer treatment.